Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog and search the HCV drug pipeline click here; for more information on HCV clinical trials click here
Thursday, May 26, 2011
New Drugs Encouraging for African Americans with Hepatitis C
The current standard of treatment of interferon and ribavirun has only been effective in curing 38 to 40 percent of patients with chronic hepatitis C genotype 1. In clinical trials, Victrelis and Incivek, when working in concert with interferon and ribavirun, cured 65 to 75 percent of people with chronic disease and Victrelis-alone doubled the previous cure rate among African Americans.